New AIDS Clinical Trials Unit Study Opens
December 30, 2003
ACTG Study 5142
A study to compare the effectiveness of three regimens for the initial treatment of HIV Infection
The study will examine the use of a lopinavir/ritonavir (a ritonavir-enhanced, second generation protease inhibitor)-based regimen, a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen, and a nucleoside-sparing regimen as the first treatment of HIV-1 infection.
The study will last for about three years.
Exams and lab tests provided at no cost. Only TDF, EFV, LPV/r, and d4tXR will be provided by the study.
Subjects receive $20 per study visit.
Contact Alyssa or Lori at the ACTU at (206) 731-3184.
This article was provided by Seattle Treatment Education Project. It is a part of the publication STEP Ezine.